Integral Diagnostics (ASX:IDX) reported Wednesday attributable loss per diluted share in the fiscal first half narrowed to AU$0.0016, from a loss of AU$0.2862 per diluted share a year earlier.
Analysts polled by Visible Alpha were expecting earnings per share of AU$0.0006.
Revenue from ordinary activities for the six months Dec. 31, 2024, was AU$252.9 million, up 9% from AU$231.3 million in the same period last year. Analysts surveyed by Visible Alpha expected AU$250.6 million.
The radiologist and diagnostic imaging provider replacement and growth capital expenditure for the fiscal year to reach AU$60 million to AU$65 million.
The board declared an interim dividend of AU$0.025 per share, unchanged from the previous reported period, payable on April 7 to shareholders on record as of March 7.
Price (AUD): $2.86, Change: $-0.030, Percent Change: -1.04%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.